Protalix Biotherapeutics, Inc. (PLX)
2.475
+0.08
(+3.12%)
USD |
NYAM |
Aug 26, 16:00
2.475
0.00 (0.00%)
After-Hours: 20:00
Protalix Biotherapeutics Shareholders Equity (Quarterly) : 71.40M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 71.40M |
| March 31, 2026 | 67.23M |
| December 31, 2025 | 48.23M |
| September 30, 2025 | 52.91M |
| June 30, 2025 | 49.90M |
| March 31, 2025 | 45.21M |
| December 31, 2024 | 43.21M |
| September 30, 2024 | 32.44M |
| June 30, 2024 | 28.58M |
| March 31, 2024 | 29.79M |
| December 31, 2023 | 33.57M |
| September 30, 2023 | 38.25M |
| June 30, 2023 | 39.00M |
| March 31, 2023 | 1.008M |
| December 31, 2022 | -10.64M |
| September 30, 2022 | -11.51M |
| June 30, 2022 | -9.889M |
| March 31, 2022 | -7.486M |
| December 31, 2021 | -6.036M |
| September 30, 2021 | 0.213M |
| June 30, 2021 | 3.841M |
| March 31, 2021 | 14.50M |
| December 31, 2020 | -27.04M |
| September 30, 2020 | -33.32M |
| June 30, 2020 | -34.76M |
| Date | Value |
|---|---|
| March 31, 2020 | -30.88M |
| December 31, 2019 | -70.32M |
| September 30, 2019 | -70.85M |
| June 30, 2019 | -67.48M |
| March 31, 2019 | -59.86M |
| December 31, 2018 | -52.88M |
| September 30, 2018 | -47.94M |
| June 30, 2018 | -42.74M |
| March 31, 2018 | -39.44M |
| December 31, 2017 | -31.29M |
| September 30, 2017 | -26.07M |
| June 30, 2017 | -20.67M |
| March 31, 2017 | -68.47M |
| December 31, 2016 | -9.957M |
| September 30, 2016 | -15.10M |
| June 30, 2016 | -7.976M |
| March 31, 2016 | 2.65M |
| December 31, 2015 | |
| September 30, 2015 | -68.51M |
| June 30, 2015 | -65.14M |
| March 31, 2015 | -61.15M |
| December 31, 2014 | -55.60M |
| September 30, 2014 | -47.69M |
| June 30, 2014 | -39.79M |
| March 31, 2014 | -33.58M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Altimmune, Inc. | 474.21M |
| Taysha Gene Therapies, Inc. | 387.27M |
| Humacyte, Inc. | 31.26M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 110.34M |
| Total Liabilities (Quarterly) | 38.93M |
| Debt to Equity Ratio | 0.1289 |
| Current Ratio | 2.938 |
| Net Debt Paydown Yield | -0.42% |